medRxiv-Exclusive! “Vaccinated at Higher Risk for Covid Infection and Hospitalization”

By VT - Fabio G. C. Carisio - July 27, 2023  - Vital, Heavy Study by Estonian University of TartuBy

Exclusive! “Vaccinated at Higher Risk for Covid Infection and Hospitalization”

«In Cohort 3, individuals with vaccine-induced immunity were at higher risk than those with natural immunity for infection (Delta aHR 4.90, 95%CI 4.48-5.36; Omicron 1.13, 95%CI 1.06-1.21) and hospitalization (Delta aHR 7.19, 95%CI 4.02-12.84). These results show that the risk of infection and severe COVID-19 are driven by personal immunity history and the variant of SARS-CoV-2 causing infection».

In three lines, a study by the University of Tartu (Estonia) practically confirms that the Covid vaccines are useless: if not to run the risk of various serious pathologies connected to the toxic Spike protein or of contracting the so-called “Covid-19 breakthrough” which has already led other scientists to detect not only the “vaccine failure” of mRNA or mDNA gene serums but even the risk that they themselves are the cause of the disease that they should prevent with an immunization process.

The conclusions of the medical analysis confirm what has already emerged from other scientific publications on the greater risks of contracting Covid-19 after vaccination. The links to previous Gospa News articles were obviously added afterward.

The research carried out with the support of the European Regional Development Fund (RITA 1/02-120), Estonian Research Council (grants PRG1197, PRG198), and European Social Fund via the IT Academy program, was published in pre-print on 23 July 2023 in the authoritative medical journal MedRxiv (partner of the British Medical Journal). This means that it has not yet been peer-reviewed but has in return been approved by the Research Ethics Committee of the University of Tartu.

The study was conducted by various professors and researchers from the University of Tartu: Anneli Uuskula, first signatory, Heti Pisarev, and Anna Tisler. Tatjana Meister, Kadri Suija from the Department of Family Medicine and Public Health, Kristi Huik from the Institute of Biomedicine and Translational Medicine, Aar Abroi from the Institute of Technology, Raivo Kolde from the Institute of Computer Science and Krista Fisher from the Institute of Mathematics and Statistics (link to the paper at the end of the page).

The statistical research was conducted on a very significant sample and equal to almost a third of the inhabitants of Estonia where 869,372 are vaccinated with a coverage of 65.36% given that vaccination has always remained on a voluntary basis.

The scientists explain in the study:

«The source population for this analysis consisted of 343 501 individuals aged 18 years or older. Based on various histories of immunity-conferring events (i.e., infection and/or vaccination) from 26 February 2020 to 25 June 2021, we determined four exposure states:

• (i) Individuals with no immunity (SARS-CoV-2 immune-naïve) were defined as those who were unvaccinated and did not have documented previous SARS-CoV-2 infections (n = 130 874);
• (ii) Individuals with natural immunity (the recovered, unvaccinated cohort) were those with a documented previous infection but without previous vaccination (n = 47 491);
• (iii) Individuals with vaccine-induced SARS-CoV-2 immunity (vaccinated-only cohort) were those without previously recorded infections who received a full vaccination course (BNT162b2; mRNA-1273; AZD1222; Ad26.COV2. S) (n = 127 460); and
• (iv) Individuals with hybrid SARS-CoV-2 immunity (the recovered, vaccinated cohort) were defined as those with documented previous infections who received at least one vaccine dose (n = 23 671)».

The conclusion summarized in the abstract of the study is sufficient to question once again the efficacy of gene serums (equivalent to true gene therapies without adequate European health certification according to the study by a French biologist). Furthermore, the tables with numbers leave no room for doubt.

«A large proportion of the world's population has some form of immunity against SARS-CoV-2, through either infection (natural), vaccination, or both (hybrid). This retrospective cohort study used data on SARS-CoV-2, vaccination, and hospitalization from the national health system from February 2020 to June 2022 and Cox regression modeling to compare those with natural immunity to those with no (Cohort1, n=92917), hybrid (Cohort2, n=46813), and vaccine (Cohort3, n=252414) immunity».

«In Cohort 1, those with natural immunity were at lower risk for infection during the Delta (aHR 0.17, 95%CI 0.15-0.18) and higher risk (aHR 1.24, 95%CI 1.18-1.32) during the Omicron period than those with no immunity. Natural immunity conferred substantial protection against COVID-19 hospitalization. Cohort 2 – in comparison to natural immunity hybrid immunity offered strong protection during the Delta (aHR 0.61, 95%CI 0.46-0.80) but not the Omicron (aHR 1.05, 95%CI 0.93-1.1) period. COVID-19-hospitalization was extremely rare among individuals with hybrid immunity».

«In Cohort 3, individuals with vaccine-induced immunity were at higher risk than those with natural immunity for infection (Delta aHR 4.90, 95%CI 4.48-5.36; Omicron 1.13, 95%CI 1.06-1.21) and hospitalization (Delta aHR 7.19, 95%CI 4.02-12.84). These results show that the risk of infection and severe COVID-19 are driven by personal immunity history and the variant of SARS-CoV-2 causing infection».

The researchers at the University of Tartu then analyze the dynamics of the infection in detail.

«The primary outcome was laboratory-confirmed SARS-CoV-2 infection occurring after the baseline date: (i) at any time for individuals with no immunity; (ii) after 60 days of recovery from a previous infection for individuals with natural immunity (i.e., reinfection);[18] (iii) after being vaccinated for at least 14 days for individuals with vaccine-induced immunity (SARS-CoV-2 vaccination only) (i.e., breakthrough infection); and (iii) after being vaccinated for at least 14 days or after 60 days [28] of recovery from a previous infection, whichever came later, for individuals with hybrid immunity».

The doctors have not only detected the cases of contagion, including those of “Covid breakthrough” that has alarmed many of their colleagues in the US and in Asia instead are minimized in Italy and in the European Union, but also the cases of hospitalization for a severe form of the disease.

«The second outcome was hospitalization with COVID-19 as the reason for admission. This was defined as SARS-CoV-2-related hospitalization occurring from 3 days before to 14 days after a positive SARS-CoV-2 test and the presence of at least one of the following diagnoses (ICD-10) in relation to hospitalization: U07.1, U07.2, acute respiratory tract infections (J00– J06, J12, J15-J18, J20-J22, J46) or severe complications of lower respiratory tract infections (J80–84, J85–J86).[29] The follow-up duration was counted in days until the date of an outcome, vaccination (for individuals with natural or no immunity), death, or end of the study period (23 February 2022), whichever occurred first».

Now for the Italian, European and US health authorities who have built a whirlwind of millionaire deals around the Covid vaccines, it will be more difficult to continue to support the efficacy and safety that have been denied by the Italian Medicines Agency (AIFA) itself in relation to the more fragile.

As the US Department of Health and Human Services (HHS), the Italian Ministry of Health led by Professor Orazio Schillaci, implicated in very serious conflicts of interest with the Big Pharma of mRNA gene serums, continues to recommend even the fifth dose to the most fragile people…

Fabio Giuseppe Carlo Carisio
© COPYRIGHT GOSPA NEWS

MAIN SOURCES

MEDRXIV – Risk of SARS-CoV-2 infection and hospitalization in individuals with natural, vaccine-induced and hybrid immunity: a retrospective population-based cohort study from Estonia

GOSPA NEWS – WUHAN-GATES DOSSIER

GOSPA NEWS – WEAPONS LOBBY DOSSIER

     Fabio is the Director and Editor of Gospa News

Fabio Giuseppe Carlo Carisio, born on 24/2/1967 in Borgosesia, started working as a reporter when he was only 19 years old in the alpine area of Valsesia, Piedmont, his birth region in Italy. After studying literature and history at the Catholic University of the Sacred Heart in Milan, he became director of the local newspaper Notizia Oggi Vercelli and specialized in judicial reporting.